BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 38069407)

  • 21.
    Maeshima R; Moulding D; Stoker AW; Hart SL
    Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
    Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
    Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
    Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
    J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of hub genes and their correlation with infiltration of immune cells in
    Chen J; Sun M; Chen C; Jiang B; Fang Y
    Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroblastoma and the epigenome.
    Fetahu IS; Taschner-Mandl S
    Cancer Metastasis Rev; 2021 Mar; 40(1):173-189. PubMed ID: 33404859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
    Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
    J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.
    Ciaccio R; De Rosa P; Aloisi S; Viggiano M; Cimadom L; Zadran SK; Perini G; Milazzo G
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN and HIF-1 directly regulate
    Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
    Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
    Tao L; Mohammad MA; Milazzo G; Moreno-Smith M; Patel TD; Zorman B; Badachhape A; Hernandez BE; Wolf AB; Zeng Z; Foster JH; Aloisi S; Sumazin P; Zu Y; Hicks J; Ghaghada KB; Putluri N; Perini G; Coarfa C; Barbieri E
    Nat Commun; 2022 Jun; 13(1):3728. PubMed ID: 35764645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma.
    Shaliman D; Takenobu H; Sugino RP; Ohira M; Kamijo T
    Eur J Cell Biol; 2022; 101(3):151238. PubMed ID: 35636260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
    Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
    Lu F; Mu B; Jin G; Zhu L; Mu P
    Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.